KK2 - Short of dropping a piano on the heads of the retail shareholders to get their attention the company has, by its actions indicated that something is about to happen without a NASDAQ listing.

This week we are now at 1.5yrs past the point where the rockstar patients in this now Phase II trial may otherwise not have been with us. The 1.5 years of extended life adds about US$ 9 billion of potential sales for the existing standard of care drug sales for mCRPC. There have been a couple of important reports come out supporting the theory on ZEN-3694 in the past week. Magically RVX closed a US$ 20 mil PP. Zenith close a US$ 4.4 mil PP that was supposed to be US$ 25 mil all in the last week. The company(ZEL or RVX) is presenting at Juniors In The News event in New York City this week, which I don't remember them ever presenting at, as well as the Rodmen and Renshaw conference.

When I add this all up I don't think a U.S. listing will ever happen for ZEL before something else happens.

All IMO

tada